Failure of Natalizumab to Prevent Relapses in Neuromyelitis Optica

Abstract

Our results suggest that natalizumab fails to control disease activity in patients with NMO. Neuromyelitis optica should be considered as a differential diagnosis in patients with suspected MS who are unresponsive to natalizumab therapy.